Patents by Inventor Jennifer Richer

Jennifer Richer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for determining breast cancer treatment
    Patent number: 11221334
    Abstract: The present invention provides a method for determining a treatment procedure for breast cancer, a method of predicting a likelihood of success in treating breast cancer, and a method for selecting an endocrine therapy agent for treating breast cancer. In particular, methods of the present invention rely on the amount of androgen receptor (AR) and estrogen receptor (ER) in a tissue sample.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 11, 2022
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Jennifer Richer Mouchantat
  • Treatment of Breast Cancer
    Publication number: 20210069154
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 11, 2021
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer
    Patent number: 10434075
    Abstract: Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: October 8, 2019
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Marc B. Cox, Jennifer Richer
  • Treatment of Breast Cancer
    Publication number: 20190262315
    Abstract: The disclosure describes compounds useful for treating breast cancers.
    Type: Application
    Filed: October 24, 2018
    Publication date: August 29, 2019
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • METHOD FOR DETERMINING BREAST CANCER TREATMENT
    Publication number: 20190113515
    Abstract: The present invention provides a method for determining a treatment procedure for breast cancer, a method of predicting a likelihood of success in treating breast cancer, and a method for selecting an endocrine therapy agent for treating breast cancer. In particular, methods of the present invention rely on the amount of androgen receptor (AR) and estrogen receptor (ER) in a tissue sample.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 18, 2019
    Inventor: Jennifer Richer Mouchantat
  • Method for determining breast cancer treatment
    Patent number: 10175240
    Abstract: The present invention provides a method for determining a treatment procedure for breast cancer, a method of predicting a likelihood of success in treating breast cancer, and a method for selecting an endocrine therapy agent for treating breast cancer. In particular, methods of the present invention rely on the amount of androgen receptor (AR) and estrogen receptor (ER) in a tissue sample.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 8, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Jennifer Richer Mouchantat
  • Treatment of breast cancer
    Patent number: 10111861
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: October 30, 2018
    Assignees: Medivation Prostate Therapeutics, Inc., The Regents of the University of Colorado, a Body Corporate
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • FKBP52-SPECIFIC ANDROGEN RECEPTOR INHIBITOR, MJC13, FOR USE IN TREATING BREAST CANCER
    Publication number: 20170360725
    Abstract: Embodiments of the current invention include methods and compositions for treating breast cancer by administering an effective amount of MJC13 to a subject in need thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Applicants: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Marc B. Cox, Jennifer Richer
  • Treatment of Breast Cancer
    Publication number: 20170087132
    Abstract: This disclosure describes the use of one or more compounds that fall within the scope of one or more structural formula I, II, III, IV, V, or VI for treating triple negative breast cancer. Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • Treatment of breast cancer
    Patent number: 9517229
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: December 13, 2016
    Assignees: MEDIVATION PROSTATE THERAPEUTICS, INC., THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • METHOD FOR DETERMINING BREAST CANCER TREATMENT
    Publication number: 20150253329
    Abstract: The present invention provides a method for determining a treatment procedure for breast cancer, a method of predicting a likelihood of success in treating breast cancer, and a method for selecting an endocrine therapy agent for treating breast cancer. In particular, methods of the present invention rely on the amount of androgen receptor (AR) and estrogen receptor (ER) in a tissue sample.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 10, 2015
    Inventor: Jennifer Richer Mouchantat
  • TREATMENT OF BREAST CANCER
    Publication number: 20140296312
    Abstract: The disclosure describes the use of one or more compounds that fall within the scope of one or more of structural formulae I, II, III, IV, V, or VI for treating triple negative breast Compounds useful for treating breast cancer include those compounds of formulae I, II, III, IV, V, or VI that inhibit proliferation of breast cancer cells and/or lead to the death of breast cancer cells, especially triple negative breast cancer.
    Type: Application
    Filed: July 27, 2012
    Publication date: October 2, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF COLORADO, MEDIVATION PROSTATE THERAPEUTICS, INC.
    Inventors: Andrew A. Protter, Jennifer Richer, Dawn Cochrane
  • MiRNAs dysregulated in triple-negative breast cancer
    Patent number: 8507195
    Abstract: The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: August 13, 2013
    Assignee: The Regents of the University of Colorado
    Inventors: Jennifer Richer, Dawn Cochrane, Steven M. Anderson
  • MIRNAS DYSREGULATED IN TRIPLE-NEGATIVE BREAST CANCER
    Publication number: 20120214864
    Abstract: The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.
    Type: Application
    Filed: August 16, 2010
    Publication date: August 23, 2012
    Inventors: Jennifer Richer, Dawn Cochrane, Steven M. Anderson
  • Progesterone receptor-regulated gene expression and methods related thereto
    Publication number: 20040132086
    Abstract: Disclosed are expression profiles of genes that are regulated by progesterone receptors, and particularly by progesterone receptor isoforms PR-A and PR-B. Methods for using such genes to identifying progesterone receptor agonist and antagonist ligands are described. Also described are methods for identifying isoform-specific progesterone receptor ligands, for identifying tissue-specific progesterone receptor ligands, and for determining the profile of genes regulated by progesterone receptors in a breast tumor sample. In addition, pluralities of polynucleotides from genes that are regulated by progesterone receptors are disclosed, as are pluralities of antibodies that selectively bind to proteins encoded by such genes.
    Type: Application
    Filed: February 10, 2004
    Publication date: July 8, 2004
    Applicant: The Regents of the University of Colorado
    Inventors: Kathryn B. Horwitz, Jennifer Richer
  • Progesterone receptor-regulated gene expression and methods related thereto
    Patent number: 6750015
    Abstract: Disclosed are expression profiles of genes that are regulated by progesterone receptors, and particularly by progesterone receptor isoforms PR-A and PR-B. Methods for using such genes to identifying progesterone receptor agonist and antagonist ligands are described. Also described are methods for identifying isoform-specific progesterone receptor ligands, for identifying tissue-specific progesterone receptor ligands, and for determining the profile of genes regulated by progesterone receptors in a breast tumor sample. In addition, pluralities of polynucleotides from genes that are regulated by progesterone receptors are disclosed, as are pluralities of antibodies that selectively bind to proteins encoded by such genes.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: June 15, 2004
    Inventors: Kathryn B. Horwitz, Jennifer Richer
  • Progesterone receptor-regulated gene expression and methods related thereto
    Publication number: 20030027208
    Abstract: Disclosed are expression profiles of genes that are regulated by progesterone receptors, and particularly by progesterone receptor isoforms PR-A and PR-B. Methods for using such genes to identifying progesterone receptor agonist and antagonist ligands are described. Also described are methods for identifying isoform-specific progesterone receptor ligands, for identifying tissue-specific progesterone receptor ligands, and for determining the profile of genes regulated by progesterone receptors in a breast tumor sample. In addition, pluralities of polynucleotides from genes that are regulated by progesterone receptors are disclosed, as are pluralities of antibodies that selectively bind to proteins encoded by such genes.
    Type: Application
    Filed: March 21, 2001
    Publication date: February 6, 2003
    Inventors: Kathryn B. Horwitz, Jennifer Richer